MedTrace Logo

BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

NCT06913712 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-22

No results posted yet for this study

Summary

1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments.
2. To establish the BMI at which this disease occurs.
3. To establish how much the BMI must be reduced to cure this disease.
4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion

Conditions

  • Idiopathic Intracranial Hypertension (IIH)

Interventions

OTHER

Weight loss without pharmacotherapy

The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.

Sponsors & Collaborators

  • University of Valencia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-27
Primary Completion
2028-05-01
Completion
2028-05-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06913712 on ClinicalTrials.gov